Using CRISPR/Cas9 to model human liver disease.

导出 LinkOut

翻译打印收藏纠错

第一作者： Michele,Alves-Bezerra

第一单位： Center for Cell and Gene Therapy, Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA.

作者： Michele,Alves-Bezerra ^[1] ; Nika,Furey ^[2] ; Collin G,Johnson ^[1] ; Karl-Dimiter,Bissig ^[2]

作者单位： Center for Cell and Gene Therapy, Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA. ^[1] Stem Cells and Regenerative Medicine Center (STAR), Baylor College of Medicine, Houston, TX, USA. ^[2] Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, TX, USA. ^[3] Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA. ^[4] Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA. ^[5] Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, USA. ^[6]

DOI 10.1016/j.jhepr.2019.09.002

PMID 32039390

发布时间 2022-01-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

JHEP reports

2019年1卷5期

392-402页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Using CRISPR/Cas9 to model human liver disease.

JHEP reports

相似文献

JHEP reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Using CRISPR/Cas9 to model human liver disease.

JHEP reports

相似文献

JHEP reports

相关期刊

检索历史清除